Pharmaceuticals

Postherpetic Neuralgia (PHN) Market Overview 2026–2030 With Insights On Industry Developments

May 4, 2026May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Postherpetic Neuralgia (PHN) Market Expected To Reach Based On Its 2026 Value?

The postherpetic neuralgia (phn) market has experienced significant growth in recent years. It is anticipated to increase from $0.77 billion in 2025 to $0.82 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. The historical expansion of this market can be attributed to elements such as an escalating incidence of herpes zoster infections, a scarcity of treatment alternatives for neuropathic pain, a reliance on opioid-based pain management strategies, an expanding elderly demographic, and the progressive development of hospital pain management provisions.

The market for postherpetic neuralgia (phn) is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $1.06 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. Factors driving this growth during the projected period include the emergence of targeted neuropathic pain treatments, increased use of biologic and branded medications, the expansion of online pharmacy distribution networks, a heightened emphasis on patient-centered pain management strategies, and the proliferation of outpatient and ambulatory care facilities. Key trends anticipated within this timeframe encompass the increasing incidence of shingles among the elderly population, a greater shift towards non-opioid pain relief methods, the expanding application of transdermal and topical solutions for pain, a surging need for sustained chronic pain management, and enhanced understanding leading to earlier detection of phn.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24664&type=smp

What Leading Drivers Are Supporting The Postherpetic Neuralgia (PHN) Market Expansion?

The postherpetic neuralgia (PHN) market is anticipated to experience growth driven by the rising prevalence of chronic pain conditions. Chronic pain is characterized by persistent or recurring discomfort lasting over three months, often extending beyond the typical recovery period from an illness or injury, thus affecting an individual’s daily functioning and quality of life. This widespread occurrence of chronic pain is attributed to the aging population, as older adults are more prone to degenerative ailments like arthritis and neuropathy that lead to sustained pain. Postherpetic neuralgia proves beneficial for chronic pain research by providing a clear model for studying nerve-related pain mechanisms and evaluating long-term treatment strategies. For example, in January 2024, a report from the Office for Health Improvement and Disparities, a UK-based government department, indicated that about 18.4% of people aged 16 and over reported having a long-term musculoskeletal (MSK) condition in 2023, which was an increase from 17.6% in 2022. Hence, the increasing prevalence of chronic pain conditions is propelling the growth of the postherpetic neuralgia (PHN) market.

Which Segment Classifications Are Used In The Postherpetic Neuralgia (PHN) Market Segment Analysis?

The postherpetic neuralgia (phn) market covered in this report is segmented –

1) By Type: Patches, Drugs, Opioids

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End Users: Hospitals, Clinics, Other End Users

Subsegments:

1) By Patches: Transdermal Drug Delivery Patches, Analgesic Patches

2) By Drugs: Prescription Drugs, Over-The-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologic Drugs

3) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic Opioids, Opioid Analgesics, Opioid Antagonists

What Trends Are Affecting The Direction Of The Postherpetic Neuralgia (PHN) Market?

Leading companies within the postherpetic neuralgia (PHN) market are prioritizing the acquisition of regulatory clearances to broaden their product offerings, gain a competitive edge, and address the substantial unmet clinical demand for more efficacious and tolerable treatments. Regulatory approvals denote the formal authorizations issued by governmental health authorities, enabling a drug or therapy to be legally sold and utilized for a specific medical condition. As an illustration, in February 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical enterprise, secured final approval from the United States Food and Drug Administration to manufacture and market once-daily generic Gabapentin Tablets in 300 mg and 600 mg strengths, specifically indicated for managing postherpetic neuralgia (PHN). These gabapentin tablets are intended for treating PHN, which is a form of neuropathic pain resulting from nerve damage caused by the reactivation of the varicella-zoster virus. For PHN, the typical dosing begins with 300 mg on the initial day, increases to 600 mg (300 mg twice daily) on the second day, and reaches 900 mg (300 mg three times daily) on the third day, with titration possible up to a maximum of 1800 mg per day (600 mg three times daily) as necessary for pain relief.

Which Firms Are Contributing To The Postherpetic Neuralgia (PHN) Market Ecosystem?

Major companies operating in the postherpetic neuralgia (phn) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Haisco Pharmaceutical Group Co. Ltd., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Sanofi S.A., Grünenthal GmbH, Endo International plc, Purdue Pharma L.P., Hikma Pharmaceuticals plc, Cipla Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd.

Get The Full Postherpetic Neuralgia (PHN) Market Report:

https://www.thebusinessresearchcompany.com/report/postherpetic-neuralgia-phn-global-market-report

Which Region Dominates The Postherpetic Neuralgia (PHN) Market By Market Share?

North America was the largest region in the postherpetic neuralgia (PHN) market in 2025. The regions covered in the postherpetic neuralgia (phn) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Postherpetic Neuralgia (PHN) Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/postherpetic-neuralgia-phn-global-market-report

Browse Through More Reports Similar to the Global Postherpetic Neuralgia (PHN) Market 2026, By The Business Research Company

Neuralgia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Breast Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-implants-global-market-report

Ocular Implants Market Report 2026

https://www.thebusinessresearchcompany.com/report/ocular-implants-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795